Reprogramming.
Hematopoiesis.
Immunity.
Lab
We are studying how hematopoietic cell fate is specified, maintained, and eventually modified or reversed. Inspired from the fields of stem cell biology, immunology, and cancer we use an interdisciplinary approach to mechanistically understand hematopoietic and immune cell identities and translate our findings into novel gene and cell therapies.
Research
Merging Stem Cells with Immunology by Cell Fate Reprogramming. Learn more about our research lines:
Latest Publications
In Vivo Dendritic Cell Reprogramming for Cancer Immunotherapy
Ervin Ascic, Fritiof Åkerström, Malavika Sreekumar Nair, André Rosa, Ilia Kurochkin, Olga Zimmermannova, Xavier Catena, Nadezhda Rotankova, Charlotte Veser, Michal Rudnik, Tommaso Ballocci, Tiffany Schärer, Xiaoli Huang, Maria de Rosa Torres, Emilie Renaud, Marta Velasco Santiago, Özcan Met, David Askmyr, Malin Lindstedt, Lennart Greiff, Laure-Anne Ligeon, Irina Agarkova, Inge Marie Svane, Cristiana F. Pires, Fábio F. Rosa, and Carlos-Filipe Pereira
September 5, 2024
Science
GATA2 Mitotic Bookmarking Is Required for Definitive Haematopoiesis
Rita Silvério-Alves, Ilia Kurochkin, Anna Rydström, Camila Vazquez Echegaray, Jakob Haider, Matthew Nicholls, Christina Rode, Louise Thelaus, Aida Yifter Lindgren, Alexandra Gabriela Ferreira, Rafael Brandão, Jonas Larsson, Marella de Bruijn, Javier Martin-Gonzalez, Carlos-Filipe Pereira
August 14, 2023 / 14:4645
Nature Communications
Team
We are a diverse group – molecular biologists, MDs, PharmDs, tumor immunologists, stem cell biologists and computational scientists – at all career stages. We architect strategies to dissect and manipulate immune cell identity.
Looking for an opportunity? Join our international team!
Funders
Latest News
The European Innovation Council (EIC) awards the project Repro-TIL with an EIC Transition grant
The project Repro-TIL – “Breakthrough Neoantigen-specific Tumor-Infiltrating Lymphocyte Therapies Through Novel Dendritic Cell Reprogramming” – secures a Transition grant from the European Innovation Council (EIC). Coordinated by Asgard Therapeutics, this project joins the expertise of the Pereira Lab and Dr. Inge Marie Svane’s group at Herlev Hospital (Denmark).
Camille Chatelain Awarded a MSCA Postdoctoral Fellowship
The researcher Camille Chatelain from Pereira Lab was awarded a Marie Skłodowska-Curie Actions (MSCA) Postdoctoral Fellowship. MSCA Postdoctoral Fellowships aim to provide researchers with the tools to develop their own projects and advance their careers, while promoting excellence and innovation as prime values. Showcasing a valuable contribution to the field of immunotherapy, Camille Chatelain’s ExpandTILs was one of the selected 1696 projects among 10,360 applications.
Filipe Pereira is Welcomed as a SciLifeLab Group Leader
Filipe Pereira is joining the SciLifeLab community as one of its Group Leaders – a set of key SciLifeLab members whose contributions to biology and technology promote excellence within the life sciences environment in Sweden and internationally.